Critical period for dopaminergic neuroprotection by hormonal replacement in menopausal rats

Neurobiology of Aging

Volumn 36, Issue 2, 2015, Pages 1194-1208

  Rodriguez Perez, Ana I ^a,c   Borrajo, Ana ^a,c   Valenzuela, Rita ^a,c   Lanciego, Jose L ^b,c   Labandeira Garcia, Jose L ^a,c  

^a Universidade de Santiago de Compostela and Instituto de Investigación Sanitaria de Santiago de Compostela   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

Author keywords

Critical period; Estrogen; Menopause; Ovariectomy; Parkinson

Indexed keywords

ANGIOTENSIN; BIOLOGICAL MARKER; CANDESARTAN; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; ANGIOTENSIN RECEPTOR ANTAGONIST; NEUROPROTECTIVE AGENT; OXIDOPAMINE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CELL DEATH; CELL FUNCTION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; ENZYME ACTIVATION; ENZYME ACTIVITY; ESTROGEN THERAPY; FEMALE; HORMONE SUBSTITUTION; MENOPAUSE; MICROGLIA; NERVE CELL CULTURE; NEUROPROTECTION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RAT; SUBSTANTIA NIGRA; THERAPY EFFECT; ANIMAL; CELL CULTURE; CHEMICALLY INDUCED; DRUG EFFECTS; NERVE DEGENERATION; PARKINSON DISEASE; PATHOLOGY; PHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SPRAGUE DAWLEY RAT; TIME FACTOR;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANIMALS; CELLS, CULTURED; DOPAMINERGIC NEURONS; ESTROGEN RECEPTOR ALPHA; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; MENOPAUSE; NERVE DEGENERATION; NEUROPROTECTIVE AGENTS; OXIDOPAMINE; PARKINSON DISEASE; RATS, SPRAGUE-DAWLEY; RENIN-ANGIOTENSIN SYSTEM; TIME FACTORS;

EID: 84922773753     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2014.10.028     Document Type: Article

References (85)

1. Al Sweidi S., Sanchez M.G., Bourque M., Morissette M., Dluzen D., Di Paolo T. Oestrogen receptors and signalling pathways: implications for neuroprotective effects of sex steroids in Parkinson's disease. J.Neuroendocrinol 2012, 24:48-61.
2. Azcoitia I., Yague J.G., Garcia-Segura L.M. Estradiol synthesis within the human brain. Neuroscience 2011, 191:139-147.
3. Babior B.M. NADPH oxidase. Curr. Opin. Immunol. 2004, 16:42-47.
4. Bains M., Cousins J.C., Roberts J.L. Neuroprotection by estrogen against MPP+-induced dopamine neuron death is mediated by ERalpha in primary cultures of mouse mesencephalon. Exp. Neurol. 2007, 204:767-776.
5. Baker A.E., Brautigam V.M., Watters J.J. Estrogen modulates microglial inflammatory mediator production via interactions with estrogen receptor beta. Endocrinology 2004, 145:5021-5032.
6. Block M.L., Zecca L., Hong J.S. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat. Rev. Neurosci. 2007, 8:57-69.
7. Borrajo A., Rodriguez-Perez A.I., Diaz-Ruiz C., Guerra M.J., Labandeira-Garcia J.L. Microglial TNF-α mediates enhancement of dopaminergic degeneration by brain angiotensin. Glia 2014, 62:145-157.
8. Bourque M., Morissette M., Cote M., Soulet D., Di Paolo T. Implication of GPER1 in neuroprotection in a mouse model of Parkinson's disease. Neurobiol. Aging 2013, 34:887-901.
9. Bourque M., Morissette M., Di Paolo T. Raloxifene activates G protein-coupled estrogen receptor 1/Akt signaling to protect dopamine neurons in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice. Neurobiol. Aging 2014, 35:2347-2356.
10. Brendel A., Felzen V., Morawe T., Manthey D., Behl C. Differential regulation of apoptosis-associated genes by estrogen receptor alpha in human neuroblastoma cells. Restor. Neurol. Neurosci. 2013, 31:199-211.
11. Campos F.L., Cristovão A.C., Rocha S.M., Fonseca C.P., Baltazar G.V. GDNF contributes to oestrogen-mediated protection of midbrain dopaminergic neurones. J.Neuroendocrinol. 2012, 24:1386-1397.
12. Cerciat M., Unkila M., Garcia-Segura L.M., Arevalo M.A. Selective estrogen receptor modulators decrease the production of interleukin-6 and interferon-gamma-inducible protein-10 by astrocytes exposed to inflammatory challenge invitro. Glia 2010, 58:93-102.
13. Chen X.N., Zhu H., Meng Q.Y., Zhou J.N. Estrogen receptor-alpha and -beta regulate the human corticotropin-releasing hormone gene through similar pathways. Brain Res. 2008, 1223:1-10.
14. Clark M.A., Guillaume G., Pierre-Louis H.C. Angiotensin II induces proliferation of cultured rat astrocytes through c-Jun N-terminal kinase. Brain Res. Bull. 2008, 75:101-106.
15. Crawford G.D., Le W.D., Smith R.G., Xie W.J., Stefani E., Appel S.H. Anovel N18TG2 x mesencephalon cell hybrid expresses properties that suggest a dopaminergic cell line of substantia nigra origin. J.Neurosci. 1992, 12:3392-3398.
16. Creutz L.M., Kritzer M.F. Estrogen receptor-beta immunoreactivity in the midbrain of adult rats: regional, subregional, and cellular localization in the A10, A9, and A8 dopamine cell groups. J.Comp. Neurol. 2002, 446:288-300.
17. Daniel J.M. Estrogens, estrogen receptors, and female cognitive aging: the impact of timing. Horm. Behav. 2013, 63:231-237.
18. Das A., Smith J.A., Gibson C., Varma A.K., Ray S.K., Banik N.L. Estrogen receptor agonists and estrogen attenuate TNF-α-induced apoptosis in VSC4.1 motoneurons. J.Endocrinol. 2011, 208:171-182.
19. De Marinis E., Acaz-Fonseca E., Arevalo M.A., Ascenzi P., Fiocchetti M., Marino M., Garcia-Segura L.M. 17β-Oestradiol anti-inflammatory effects in primary astrocytes require oestrogen receptor β-mediated neuroglobin upregulation. J.Neuroendocrinol. 2013, 25:260-270.
20. de Villiers T.J., Gass M.L., Haines C.J., Hall J.E., Lobo R.A., Pierroz D.D., Rees M. Global consensus statement on menopausal hormone therapy. Climacteric 2013, 16:203-204.
21. Dean S.A., Tan J., O'Brien E.R., Leenen F.H. 17beta-estradiol downregulates tissue angiotensin-converting enzyme and ANG II type 1 receptor in female rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2004, 288:R759-R766.
22. Dluzen D. Estrogen decreases corpus striatal neurotoxicity in response to 6-hydroxydopamine. Brain Res. 1997, 767:340-344.
23. Dubal D.B., Rau S.W., Shughrue P.J., Zhu H., Yu J., Cashion A.B., Suzuki S., Gerhold L.M., Bottner M.B., Dubal S.B., Merchanthaler I., Kindy M.S., Wise P.M. Differential modulation of estrogen receptors (ERs) in ischemic brain injury: a role for ERalpha in estradiol-mediated protection against delayed cell death. Endocrinology 2006, 147:3076-3084.
24. Dziuk P.J., Cook B. Passage of steroids through silicone rubber. Endocrinology 1966, 78:208-211.
25. Färber K., Kettenmann H. Physiology of microglial cells. Brain Res. Brain Res. Rev. 2005, 48:133-143.
26. Febo M., Ferris C.F., Segarra A.C. Estrogen influences cocaine-induced blood oxygen level-dependent signal changes in female rats. J.Neurosci. 2005, 25:1132-1136.
27. Fernández N., García J.J., Diez M.J., Terán M.T., Sierra M. Rapid high-performance liquid chromatographic assay of ethynyloestradiol in rabbit plasma. J.Chromatogr. 1993, 619:143-147.
28. Gundersen H.J., Bendtsen T.F., Korbo L., Marcussen N., Moller A., Nielsen K., Nyengaard J.R., Pakkenberg B., Sorensen F.B., Vesterby A., West M.J. Some new, simple and efficient stereological methods and their use in pathological research and diagnosis. APMIS 1988, 96:379-394.
29. Hemming M.L., Selkoe D.J., Farris W. Effects of prolonged angiotensin-converting enzyme inhibitor treatment on amyloid β-protein metabolism in mouse models of Alzheimer disease. Neurobiol. Dis. 2007, 26:273-281.
30. Henze C., Hartmann A., Lescot T., Hirsch E.C., Michel P.P. Proliferation of microglial cells induced by 1-methyl-4-phenylpyridinium in mesencephalic cultures results from an astrocyte-dependent mechanism: role of granulocyte macrophage colony-stimulating factor. J.Neurochem. 2005, 95:1069-1077.
31. Hoffmann A., Cool D.R. Characterization of two polyclonal peptide antibodies that recognize the carboxy terminus of angiotensin II AT1A and AT1B receptors. Clin. Exp. Pharmacol. Physiol. 2005, 32:936-943.
32. Joglar B., Rodriguez-Pallares J., Rodríguez-Perez A.I., Rey P., Guerra M.J., Labandeira-Garcia J.L. The inflammatoryresponse in the MPTP model of Parkinson's disease is mediated by brain angiotensin: relevance to progression of the disease. J.Neurochem. 2009, 109:656-669.
33. Jones E.S., Vinh A., McCarthy C.A., Gaspari T.A., Widdop R.E. AT2 receptors: functional relevance in cardiovascular disease. Pharmacol. Ther. 2008, 120:292-316.
34. Kim M.J., Shin K.S., Chung Y.B., Jung K.W., Cha C.I., Shin D.H. Immunohistochemical study of p47Phox and gp91Phox distributions in rat brain. Brain Res. 2005, 1040:178-186.
35. Kondo T., Yoshida K., Yoshimura Y., Motohashi M., Tanayama S. Disposition of the new angiotensin II receptor antagonist candesartan cilexetil in rats and dogs. Arzneimittelforschung 1996, 46:594-600.
36. Koprich J.B., Reske,-Nielsen C., Mithal P., Isacson O. Neuroinflammation mediated by IL-1beta increases susceptibility of dopamine neurons to degeneration in an animal model of Parkinson's disease. J.Neuroinflammation 2008, 5:8.
37. Krishnamurthi K., Verbalis J.G., Zheng W., Wu Z., Clerch L.B., Sandberg K. Estrogen regulates angiotensin AT1 receptor expression via cytosolic proteins that bind to the 5' leader sequence of the receptor mRNA. Endocrinology 1999, 140:5435-5438.
38. Labandeira-Garcia J.L., Rodriguez-Pallares J., Dominguez-Meijide A., Valenzuela R., Villar-Cheda B., Rodríguez-Perez A.I. Dopamine-angiotensin interactions in the basal ganglia and their relevance for Parkinson's disease. Mov. Disord. 2013, 28:1337-1342.
39. Lanz T.V., Ding Z., Ho P.P., Luo J., Agrawal A.N., Srinagesh H., Axtell R., Zhang H., Platten M., Wyss-Coray T., Steinman L. Angiotensin II sustains brain inflammation in mice via TGF-beta. J.Clin. Invest. 2010, 120:2782-2794.
40. Lewis D.K., Johnson A.B., Stohlgren S., Harms A., Sohrabji F. Effects of estrogen receptor agonists on regulation of the inflammatory response in astrocytes from young adult and middle-aged female rats. J.Neuroimmunol. 2008, 195:47-59.
41. Liu B., Dluzen D.E. Oestrogen and nigrostriatal dopaminergic neurodegeneration: animal models and clinical reports of Parkinson's disease. Clin. Exp. Pharmacol. Physiol. 2007, 34:555-565.
42. Lizotte E., Grandy S.A., Tremblay A., Allen B.G., Fiset C. Expression, distribution and regulation of sex steroid hormone receptors in mouse heart. Cell Physiol. Biochem. 2009, 23:75-86.
43. Loghman-Adham M., Soto C.E., Inagami T., Sotelo-Avila C. Expression of components of the renin-angiotensin system in autosomal recessive polycystic kidney disease. J.Histochem. Cytochem. 2005, 53:979-988.
44. López-Martín E., Caruncho H.J., Rodríguez-Pallares J., Guerra M.J., Labandeira-García J.L. Striatal dopaminergic afferents concentrate in GDNF-positive patches during development and in developing intrastriatal striatal grafts. J.Comp. Neurol. 1999, 406:199-206.
45. Mannino C.A., South S.M., Inturrisi C.E., Quinones-Jenab V. Pharmacokinetics and effects of 17beta-estradiol and progesterone implants in ovariectomized rats. J.Pain 2005, 6:809-816.
46. Miller V.M., Black D.M., Brinton E.A., Budoff M.J., Cedars M.I., Hodis H.N., Lobo R.A., Manson J.E., Merriam G.R., Naftolin F., Santoro N., Taylor H.S., Harman S.M. Using basic science to design a clinical trial: baseline characteristics of women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS). J.Cardiovasc. Transl. Res. 2009, 2:228-239.
47. Moffatt C.A., Rissman E.F., Shupnik M.A., Blaustein J.D. Induction of progestin receptors by estradiol in the forebrain of estrogen receptor-alpha gene-disrupted mice. J.Neurosci. 1998, 18:9556-9563.
48. Morale M.C., Serra P.A., L'episcopo F., Tirolo C., Caniglia S., Testa N., Gennuso F., Giaquinta G., Rocchitta G., Desole M.S., Miele E., Marchetti B. Estrogen, neuroinflammation and neuroprotection in Parkinson's disease: glia dictates resistance versus vulnerability to neurodegeneration. Neuroscience 2006, 138:869-878.
49. Murray H.E., Pillai A.V., McArthur S.R., Razvi N., Datla K.P., Dexter D.T., Gillies G.E. Dose- and sex-dependent effects of the neurotoxin 6-hydroxydopamine on the nigrostriatal dopaminergic pathway of adult rats: differential actions of estrogen in males and females. Neuroscience 2003, 116:213-222.
50. Nickenig G., Bäumer A.T., Grohè C., Kahlert S., Strehlow K., Rosenkranz S., Stäblein A., Beckers F., Smits J.F., Daemen M.J., Vetter H., Böhm M. Estrogen modulates AT1 receptor gene expression invitro and invivo. Circulation 1998, 97:2197-2201.
51. Obermüller N., Gentili M., Gauer S., Gretz N., Weigel M., Geiger H., Gassler N. Immunohistochemical and mRNA localization of the angiotensin II receptor subtype 2 (AT2) in follicular granulosa cells of the rat ovary. J.Histochem. Cytochem. 2004, 52:545-548.
52. O'Callaghan E.L., Bassi J.K., Porrello E.R., Delbridge L.M., Thomas W.G., Allen A.M. Regulation of angiotensinogen by angiotensin II in mouse primary astrocyte cultures. J.Neurochem. 2011, 119:18-26.
53. Paxinos, G., Watson, C., 2007. The Rat Brain in Stereotatic Coordinates, sixth ed. Elsevier Academic Press, New York.
54. Piwowarska J., Radowicki S., Pachecka J. Simultaneous determination of eight estrogens and their metabolites in serum using liquid chromatography with electrochemical detection. Talanta 2010, 81:275-280.
55. Prossnitz E.R., Maggiolini M. Mechanisms of estrogen signaling and gene expression via GPR30. Mol. Cell Endocrinol. 2009, 308:32-38.
56. Przedborski S., Levivier M., Jiang H., Ferreira M., Jackson-Lewis V., Donaldson D., Togasaki D.M. Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine. Neuroscience 1995, 67:631-647.
57. Ragonese P., D'Amelio M., Callari G., Salemi G., Morgante L., Savettieri G. Age at menopause predicts age at onset of Parkinson's disease. Mov. Disord. 2006, 21:2211-2214.
58. Re R.N. Tissue renin angiotensin systems. Med. Clin. North Am. 2004, 88:19-38.
59. Rey P., Lopez-Real A., Sanchez-Iglesias S., Muñoz A., Soto-Otero R., Labandeira-Garcia J.L. Angiotensin type-1-receptor antagonists reduce 6-hydroxydopamine toxicity for dopaminergic neurons. Neurobiol. Aging 2007, 28:555-567.
60. Righi M., Mori L., De Libero G., Sironi M., Biondi A., Mantovani A., Donini S.D., Ricciardi-Castagnoli P. Monokine production by microglial cell clones. Eur. J. Immunol. 1989, 19:1443-1448.
61. Rodriguez-Pallares J., Rey P., Parga J.A., Muñoz A., Guerra M.J., Labandeira-Garcia J.L. Brain angiotensin enhances dopaminergic cell death viamicroglial activation and NADPH-derived ROS. Neurobiol. Dis. 2008, 31:58-73.
62. Rodriguez-Perez A.I., Dominguez-Meijide A., Lanciego J.L., Guerra M.J., Labandeira-Garcia J.L. Inhibition of Rho kinase mediates the neuroprotective effects of estrogen in the MPTP model of Parkinson's disease. Neurobiol. Dis. 2013, 58:209-219.
63. Rodriguez-Perez A.I., Valenzuela R., Villar-Cheda B., Guerra M.J., Labandeira-Garcia J.L. Different dopaminergic neuroprotection of hormonal replacement therapy in young and aged menopausal rats. Role of the brain angiotensin system. Brain 2012, 135:124-138.
64. Rodriguez-Perez A.I., Valenzuela R., Villar-Cheda B., Guerra M.J., Lanciego J.L., Labandeira-Garcia J.L. Estrogen and angiotensin interaction in the substantia nigra. Relevance to postmenopausal Parkinson's diseas. Exp. Neurol. 2010, 224:517-526.
65. Sauer H., Oertel W.H. Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat. Neuroscience 1994, 59:401-415.
66. Scott E.L., Zhang Q.G., Vadlamudi R.K., Brann D.W. Premature menopause and risk of neurological disease: basic mechanisms and clinical implications. Mol. Cell Endocrinol. 2014, 389:2-6.
67. Scott E., Zhang Q.G., Wang R., Vadlamudi R., Brann D. Estrogen neuroprotection and the critical period hypothesis. Front. Neuroendocrinol. 2012, 33:85-104.
68. Seshiah P.N., Weber D.S., Rocic P., Valppu L., Taniyama Y., Griendling K.K. Angiotensin II stimulation of NAD(P)H oxidase activity: upstream mediators. Circ. Res. 2002, 91:406-413.
69. Smith K.M., Dahodwala N. Sex differences in Parkinson's disease and other movement disorders. Exp. Neurol. 2014, 259:44-56.
70. Spence R.D., Wisdom A.J., Cao Y., Hill H.M., Mongerson C.R., Stapornkul B., Itoh N., Sofroniew M.V., Voskuhl R.R. Estrogen mediates neuroprotection and anti-inflammatory effects during EAE through ERα signaling on astrocytes but not through ERβ signaling on astrocytes or neurons. J.Neurosci. 2013, 33:10924-10933.
71. Stornetta R.L., Hawelu-Johnson C.L., Guyenet P.G., Lynch K.R. Astrocytes synthesize angiotensinogen in brain. Science 1988, 242:1444-1446.
72. Tapia-Gonzalez S., Carrero P., Pernia O., Garcia-Segura L.M., Diz-Chaves Y. Selective oestrogen receptor (ER) modulators reduce microglia reactivity invivo after peripheral inflammation: potential role of microglial ERs. J.Endocrinol. 2008, 198:219-230.
73. Tyree C.M., Zou A., Allegretto E.A. 17beta-Estradiol inhibits cytokine induction of the human E-selectin promoter. J.Steroid Biochem. Mol. Biol. 2002, 80:291-297.
74. Unger T. Inhibiting angiotensin receptors in the brain: possible therapeutic implications. Curr. Med. Res. Opin. 2003, 19:449-451.
75. Vegeto E., Belcredito S., Ghisletti S., Meda C., Etteri S., Maggi A. The endogenous estrogen status regulates microglia reactivity in animal models of neuroinflammation. Endocrinology 2006, 147:2263-2272.
76. Vegeto E., Benedusi V., Maggi A. Estrogen anti-inflammatory activity in brain: a therapeutic opportunity for menopause and neurodegenerative diseases. Front. Neuroendocrinol. 2008, 29:507-519.
77. Villar-Cheda B., Dominguez-Meijide A., Joglar B., Rodriguez-Perez A.I., Guerra M.J., Labandeira-Garcia J.L. Involvement of microglial RhoA/Rho-kinase pathway activation in the dopaminergic neuron death. Role of angiotensin via angiotensin type 1 receptors. Neurobiol. Dis. 2012, 47:268-279.
78. Wang J.M., Hou X., Adeosun S., Hill R., Henry S., Paul I., Irwin R.W., Ou X.M., Bigler S., Stockmeier C., Brinton R.D., Gomez-Sanchez E. Adominant negative ERβ splice variant determines the effectiveness of early or late estrogen therapy after ovariectomy in rats. PLoS One 2012, 7:e33493.
79. Wright J.W., Harding J.W. Importance of the brain angiotensin system in Parkinson's disease. Parkinsons Dis. 2012, 2012:860923.
80. Wu W.F., Tan X.J., Dai Y.B., Krishnan V., Warner M., Gustafsson J.A. Targeting estrogen receptor β in microglia and T cells to treat experimentalautoimmune encephalomyelitis. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:3543-3548.
81. Wu Z., Zheng W., Sandberg K. Estrogen regulates adrenal angiotensin type 1 receptors by modulating adrenal angiotensin levels. Endocrinology 2003, 144:1350-1356.
82. Zawada W.M., Banninger G.P., Thornton J., Marriott B., Cantu D., Rachubinski A.L., Das M., Griffin W.S., Jones S.M. Generation of reactive oxygen species in 1-methyl-4-phenylpyridinium (MPP+) treated dopaminergic neurons occurs as an NADPH oxidase-dependent two-wave cascade. J.Neuroinflammation 2011, 8:129.
83. Zhang Q.G., Raz L., Wang R., Han D., De Sevilla L., Yang F., Vadlamudi R.K., Brann D.W. Estrogen attenuates ischemic oxidative damage via an estrogen receptor alpha-mediated inhibition of NADPH oxidase activation. J.Neurosci. 2009, 29:13823-13836.
84. Zhao L., Wu T.W., Brinton R.D. Estrogen receptor subtypes alpha and beta contribute to neuroprotection and increased Bcl-2 expression in primary hippocampal neurons. Brain Res. 2004, 1010:22-34.
85. Zorad S., Dou J.T., Benicky J., Hutanu D., Tybitanclova K., Zhou J., Saavedra J.M. Long-term angiotensin II AT1 receptor inhibition produces adipose tissue hypotrophy accompanied by increased expression of adiponectin and PPARgamma. Eur. J. Pharmacol. 2006, 552:112-122.